Barr, Mylan Face Patent Suit Over Amrix ANDAs
Pennsylvania-based Cephalon filed the suit Tuesday in the U.S. District Court for the District of Delaware in response to abbreviated new drug applications Barr and Mylan submitted to the U.S. Food and Drug Administration to make generic versions of the drug.
Cephalon's Swiss subsidiary, Anesta AG, and Ohio-based Eurand...
Already a subscriber? Click here to login